Evogene Stock Shares Owned By Insiders
EVGN Stock | ILA 606.00 32.00 5.02% |
Evogene fundamentals help investors to digest information that contributes to Evogene's financial success or failures. It also enables traders to predict the movement of Evogene Stock. The fundamental analysis module provides a way to measure Evogene's intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to Evogene stock.
Evogene |
Evogene Company Shares Owned By Insiders Analysis
Evogene's Shares Owned by Insiders show the percentage of outstanding shares owned by insiders (such as principal officers or members of the board of directors) or private individuals and entities with over 5% of the total shares outstanding. Company executives or private individuals with access to insider information share information about a firm's operations that is not available to the general public.
More About Shares Owned By Insiders | All Equity Analysis
Insiders Shares | = | Executives Shares | + | Employees |
Current Evogene Shares Owned By Insiders | 3.58 % |
Most of Evogene's fundamental indicators, such as Shares Owned By Insiders, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Evogene is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
Although the research on effects of insider trading on prices and volatility is still relatively inconclusive, and investors are advised to pay close attention to the distribution of equities among company's stakeholders to avoid many problems associated with the disclosure of price-sensitive information.
Competition |
Based on the latest financial disclosure, 3.58% of Evogene are shares owned by insiders. This is 76.42% lower than that of the Biotechnology sector and 74.75% lower than that of the Health Care industry. The shares owned by insiders for all Israel stocks is 64.52% higher than that of the company.
Evogene Shares Owned By Insiders Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Evogene's direct or indirect competition against its Shares Owned By Insiders to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of Evogene could also be used in its relative valuation, which is a method of valuing Evogene by comparing valuation metrics of similar companies.Evogene is currently under evaluation in shares owned by insiders category among its peers.
Evogene Fundamentals
Return On Equity | -0.63 | |||
Return On Asset | -0.28 | |||
Operating Margin | (24.02) % | |||
Current Valuation | 8.8 M | |||
Shares Outstanding | 41.22 M | |||
Shares Owned By Insiders | 3.58 % | |||
Shares Owned By Institutions | 3.37 % | |||
Price To Book | 0.93 X | |||
Price To Sales | 73.01 X | |||
Revenue | 930 K | |||
Gross Profit | 163 K | |||
EBITDA | (26.78 M) | |||
Net Income | (27.79 M) | |||
Cash And Equivalents | 65.36 M | |||
Cash Per Share | 1.61 X | |||
Total Debt | 2.39 M | |||
Debt To Equity | 0.03 % | |||
Current Ratio | 12.74 X | |||
Book Value Per Share | 0.74 X | |||
Cash Flow From Operations | (24.72 M) | |||
Earnings Per Share | (0.72) X | |||
Target Price | 5.0 | |||
Number Of Employees | 133 | |||
Beta | 0.9 | |||
Market Capitalization | 121.59 M | |||
Total Asset | 76.3 M | |||
Retained Earnings | (90 M) | |||
Working Capital | 89 M | |||
Current Asset | 95 M | |||
Current Liabilities | 6 M | |||
Z Score | 29.8 | |||
Net Asset | 76.3 M |
About Evogene Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Evogene's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Evogene using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Evogene based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.Additional Information and Resources on Investing in Evogene Stock
When determining whether Evogene offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Evogene's financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Evogene Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Evogene Stock:Check out Investing Opportunities to better understand how to build diversified portfolios, which includes a position in Evogene. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in board of governors. For information on how to trade Evogene Stock refer to our How to Trade Evogene Stock guide.You can also try the Bond Analysis module to evaluate and analyze corporate bonds as a potential investment for your portfolios..